"The ETF holds 50 positions, but the top two dominate in a way that makes the rest almost incidental. Johnson & Johnson carries a 25.4% weight, and Eli Lilly and Company sits at 21.4%. Together they account for roughly 46.8% of the entire fund."
"Johnson & Johnson has held up well relative to the broader fund. Shares are up roughly 14% year-to-date, driven by strong pharmaceutical growth. However, JNJ faces real headwinds, including STELARA biosimilar erosion and significant litigation charges."
"Eli Lilly is the more volatile story. GLP-1 drugs Mounjaro and Zepbound have driven most of Lilly's revenue growth, with Mounjaro posting $7.41 billion in Q4 2025 revenue, up 110%. Yet, the stock has fallen roughly 15% year-to-date."
The iShares U.S. Pharmaceuticals ETF has a 0.38% expense ratio and nearly $1.1 billion in net assets. It holds 50 positions, with Johnson & Johnson and Eli Lilly dominating at 25.4% and 21.4% respectively, accounting for 46.8% of the fund. Johnson & Johnson has seen a 14% year-to-date increase but faces litigation and revenue erosion. Eli Lilly's revenue growth from GLP-1 drugs is significant, yet the stock has fallen 15% year-to-date, indicating volatility and contrasting performance between the two companies.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]